Clinical and Meibomian Lipidomic Changes After Combined Intense Pulsed Light and Triamcinolone Acetonide Therapy for Chalazion: A Retrospective Single-Arm Pre-Post Case Series.
Source: PubMed, NCBI / U.S. National Library of Medicine
To explore the clinical changes associated with intense pulsed light (IPL) combined with triamcinolone acetonide (TA) injections in patients with chalazion and to evaluate associated changes in Hospital Anxiety and Depression Scale (HADS) scores and meibomian gland lipid profiles. This study was designed as a retrospective single-arm pre-post case series involving 15 adult patients with chalazion who had not received alternative treatments for at least three months. No control group was included. The primary outcome was complete resolution of chalazion at the final follow-up (T2). Secondary outcomes included changes in ocular surface parameters (OSDI, TBUT, CFS, and SIT), psychological status assessed using the HADS, and alterations in meibomian gland lipid composition evaluated by lipidomic analysis. All patients met the predefined criteria for complete chalazion resolution at the final follow-up (T2). Significant improvements were observed, with OSDI scores decreasing from 26.27 ± 5.11 to 16.6 ± 10.42, TBUT increasing from 3.23 ± 1.05 to 7.53 ± 2.75 s, and CFS reducing from 1 ± 1.13 to 0.27 ± 0.7. Depression (HADS-D) and anxiety (HADS-A) scores also decreased significantly. The SIT increased from 9.87 ± 5.05 to 11.27 ± 7.32, though not statistically significant. Lipidomics analysis identified 719 lipids, with signific
Abstract
To explore the clinical changes associated with intense pulsed light (IPL) combined with triamcinolone acetonide (TA) injections in patients with chalazion and to evaluate associated changes in Hospital Anxiety and Depression Scale (HADS) scores and meibomian gland lipid profiles. This study was designed as a retrospective single-arm pre-post case series involving 15 adult patients with chalazion who had not received alternative treatments for at least three months. No control group was included. The primary outcome was complete resolution of chalazion at the final follow-up (T2). Secondary outcomes included changes in ocular surface parameters (OSDI, TBUT, CFS, and SIT), psychological status assessed using the HADS, and alterations in meibomian gland lipid composition evaluated by lipidomic analysis. All patients met the predefined criteria for complete chalazion resolution at the final follow-up (T2). Significant improvements were observed, with OSDI scores decreasing from 26.27 ± 5.11 to 16.6 ± 10.42, TBUT increasing from 3.23 ± 1.05 to 7.53 ± 2.75 s, and CFS reducing from 1 ± 1.13 to 0.27 ± 0.7. Depression (HADS-D) and anxiety (HADS-A) scores also decreased significantly. The SIT increased from 9.87 ± 5.05 to 11.27 ± 7.32, though not statistically significant. Lipidomics analysis identified 719 lipids, with significant reductions in sphingolipids (Cer and SM) and glycerophospholipids (LPC, LPE, PC, and PE) posttreatment (< 0.05). A negative correlation was found between DG and TBUT, and a positive correlation between MGDG O and CFS. In this retrospective single-arm pre-post case series, IPL combined with TA treatment was associated with the resolution of chalazion and improvements in several clinical and lipidomic parameters. However, these findings should be considered exploratory and interpreted with caution, as spontaneous chalazion resolution and concurrent warm compress therapy may have contributed to the observed changes.